Identifying EGFR Mutations in NSCLC and Optimizing Therapy - Episode 9
For High-Definition, Click
\With the array of effective treatment options available, It may be realistic to expect that EGFR-mutant non-small cell lung cancer (NSCLC) may evolve into a chronic disease, Mark A. Socinski, MD, hopes. At this point, there are three-generations of successful agents, with the latest iteration showing promise in hard to treat patient populations.
As research continues to explore treatment options, combination therapies are beginning to surface for patients with EGFR-mutant NSCLC, including EGFR TKIs with immune checkpoint inhibitors. Although positive, patients with EGFR-positive NSCLC represent a minority in the overall lung cancer population. Ideally, similar results could be duplicated in patients with pan-wild-type lung cancer, suggests Socinski.